Philip Friedlander
- ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
- ASSISTANT PROFESSOR Dermatology
Print Profile
Specialty
Certifications
Medical Oncology
Clinical Focus
Education
MD, Columbia University
Internship, Internal Medicine
Columbia-Presbyterian Medical CenterResidency, Internal Medicine
Columbia-Presbyterian Medical CenterFellowship, Oncology
Memorial Sloan-Kettering Cancer Center
Biography
- Dr. Friedlander received medical school training at Columbia University where he obtained his M.D. and Ph.D. degree in Biology. He remained at Columbia Presbyterian Medical Center to complete his postdoctoral training in Internal Medicine and subsequently completed a clinical fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. He then joined the faculty of the Dana Farber Cancer Institute/Brigham and Women’s Hospital as an attending physician within the Melanoma and Cutaneous Oncology Programs and as an Instructor of Medicine at Harvard Medical School. His clinical interests include the development of targeted therapies and immunotherapies for patients with melanoma, merkel cell carcinoma, advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and sebaceous gland tumors. At the Dana Farber Cancer Institute he acted as a principal investigator testing novel therapeutic approaches for melanoma including PARP inhibition, hsp90 inhibition, anti-apoptotic approaches, and immune modulatory and anti-CTLA4 based strategies. He investigated in non-melanoma skin cancers novel therapeutic strategies such as hedgehog signaling pathway inhibition in advanced basal cell carcinoma. As a member of the Division of Hematology/Medical Oncology and as the Director of the Melanoma Medical Oncology Program at Mount Sinai, he will be caring for patients with cutaneous malignancies and continue working to develop collaborative translational and basic science projects and treatments for patients with cutaneous malignancies.
In the News:
Watch Dr. Friedlander discuss a new FDA approved treatment (Erivedge) for Basal Cell Carcinoma:
KTVX-TV (ABC/Salt Lake City, Utah)
KRNV-TV (NBC/Reno, Nevada)
WNAV-AM (Baltimore, Maryland)
Clinical Trials
- A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) In Patients with Advanced Cancer
- Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Study 2)
- A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Friedlander during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Bristol-Myers Squibb; Genentech, Inc.
Scientific Advisory Board:
- Genentech, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 1st floor Room Suite 100
1425 Madison Avenue
New York, NY 10029
Icahn Medical Institute Room Tisch Cancer Inst.
1425 Madison Avenue
New York, NY 10029
1470 Madison Avenue
3rd floor
New York, NY 10029
